Fulgent Genetics (NASDAQ:FLGT) Issues FY 2026 Earnings Guidance

Fulgent Genetics (NASDAQ:FLGT) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of -2.350–2.220 for the period, compared to the consensus estimate of -1.820. The company issued revenue guidance of $330.0 million-$340.0 million, compared to the consensus revenue estimate of $351.2 million.

Analyst Ratings Changes

A number of research analysts have weighed in on FLGT shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Fulgent Genetics in a research note on Monday, July 6th. Wall Street Zen raised Fulgent Genetics from a “strong sell” rating to a “sell” rating in a report on Saturday, May 30th. Finally, Piper Sandler restated a “neutral” rating and set a $15.00 price target (down from $30.00) on shares of Fulgent Genetics in a research report on Tuesday, May 5th. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $27.00.

Fulgent Genetics Price Performance

Fulgent Genetics stock traded down $3.21 during trading hours on Friday, reaching $17.00. The company had a trading volume of 932,414 shares, compared to its average volume of 453,852. Fulgent Genetics has a 12-month low of $13.46 and a 12-month high of $31.04. The company has a 50-day moving average price of $19.32 and a 200 day moving average price of $19.27. The firm has a market cap of $482.69 million, a price-to-earnings ratio of -7.09 and a beta of 0.89.

Fulgent Genetics (NASDAQ:FLGT) last announced its quarterly earnings results on Thursday, July 30th. The company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.12). The firm had revenue of $85.39 million for the quarter, compared to analysts’ expectations of $94.00 million. Fulgent Genetics had a negative net margin of 23.04% and a negative return on equity of 3.24%. Fulgent Genetics has set its FY 2026 guidance at -2.350–2.220 EPS. As a group, research analysts expect that Fulgent Genetics will post -2.81 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Hanlin Gao sold 1,688 shares of the company’s stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $17.89, for a total transaction of $30,198.32. Following the completion of the transaction, the insider owned 990,374 shares in the company, valued at $17,717,790.86. This represents a 0.17% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Jian Xie sold 2,146 shares of the firm’s stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $17.89, for a total transaction of $38,391.94. Following the completion of the sale, the chief operating officer directly owned 367,605 shares of the company’s stock, valued at approximately $6,576,453.45. This represents a 0.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 5,980 shares of company stock valued at $106,360. 36.18% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Federated Hermes Inc. boosted its stake in shares of Fulgent Genetics by 1.2% during the 4th quarter. Federated Hermes Inc. now owns 47,102 shares of the company’s stock worth $1,237,000 after acquiring an additional 552 shares during the last quarter. Rhumbline Advisers raised its stake in Fulgent Genetics by 2.4% during the 2nd quarter. Rhumbline Advisers now owns 33,139 shares of the company’s stock valued at $659,000 after purchasing an additional 785 shares during the period. Swiss National Bank lifted its holdings in shares of Fulgent Genetics by 3.2% in the fourth quarter. Swiss National Bank now owns 39,200 shares of the company’s stock worth $1,030,000 after buying an additional 1,200 shares in the last quarter. Mackenzie Financial Corp lifted its stake in Fulgent Genetics by 11.2% in the 3rd quarter. Mackenzie Financial Corp now owns 12,155 shares of the company’s stock worth $275,000 after purchasing an additional 1,220 shares in the last quarter. Finally, Kestra Advisory Services LLC purchased a new stake in shares of Fulgent Genetics in the fourth quarter worth about $35,000. Hedge funds and other institutional investors own 48.06% of the company’s stock.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc (NASDAQ: FLGT) is a California-based company specializing in high-complexity genetic testing and diagnostic services. Operating from its headquarters in Temple City, Fulgent leverages next-generation sequencing (NGS) technologies and advanced bioinformatics to deliver a broad range of clinical and research assays. The company’s infrastructure includes CAP- and CLIA-certified laboratories, enabling it to process large volumes of samples with rapid turnaround times.

Fulgent’s product portfolio encompasses hereditary cancer panels, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, and infectious disease assays including COVID-19 diagnostics.